A Phase I Trial of AMG 386 and Temsirolimus in Advanced Solid Tumors With an Expansion Cohort in Uterine Cancer, Renal Cell Carcinoma and Carcinoid Tumors

Trial Profile

A Phase I Trial of AMG 386 and Temsirolimus in Advanced Solid Tumors With an Expansion Cohort in Uterine Cancer, Renal Cell Carcinoma and Carcinoid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Dec 2015

At a glance

  • Drugs Trebananib (Primary) ; Temsirolimus
  • Indications Carcinoid tumour; Renal cell carcinoma; Solid tumours; Uterine cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Dec 2015 Results published in the Investigational New Drugs
    • 05 Oct 2015 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 02 Mar 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Sep 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top